Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Designation of Benchmark centers of the Spanish National Health System in December 2024

In January 2025, it was announced by the Interterritorial Council for the Spanish National Health System that two Benchmark centers, departments, and units of the National Health System (CSURs) were designated in December 2024 for the following previously approved procedure in the cardiovascular field: Electrode removal in adults. In addition, two CSURs were redesignated for the following previously approved pathology: Familial heart disease.

The CSURs are centers accredited by the Ministry of Health to treat rare or complex pathologies.

See the full details in Spanish here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.